Sugi Predict

Sugi Predict / Compounds / SCHEMBL1799092

SCHEMBL1799092

SCHEMBL1799092

O=C(O)CNc1ccc(OCc2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.61
▸ RAB9A P51151 4/20 0.61
▸ LTA4H P09960 4/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ MEN1 O00255 2/20 0.61
▸ KMT2A Q03164 2/20 0.61
▸ TP53 P04637 1/20 0.61
▸ GAA P10253 1/20 0.61
▸ MAPT P10636 1/20 0.61
▸ BLM P54132 1/20 0.61
▸ ATM Q13315 1/20 0.61
▸ NR4A1 P22736 1/20 0.58
▸ NR4A2 P43354 1/20 0.58
▸ NR4A3 Q92570 1/20 0.58
▸ FFAR1 O14842 1/20 0.58
▸ FFAR4 Q5NUL3 1/20 0.58
▸ ALDH1A1 P00352 2/20 0.57
▸ CYP1A2 P05177 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5817631 0.89 SMN1; SMN2 (0.64) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5816975 0.89 SMN1; SMN2 (0.64) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL10832371 0.86 NPC1 (0.57) NPC1RAB9ALTA4HSMN1; SMN2MEN1
SCHEMBL6630458 0.86 RAB9A (0.65) NPC1RAB9ALTA4HSMN1; SMN2MEN1
SCHEMBL401984 0.85 MEN1 (0.67) NPC1RAB9ALTA4HSMN1; SMN2MEN1
SCHEMBL9874676 0.84 NPC1 (0.49) NPC1RAB9ALTA4HSMN1; SMN2MEN1
SCHEMBL3039365 0.84 HRH3 (0.67) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5287947 0.83 FFAR1 (0.62) RAB9AMEN1KMT2AGAAMAPT
SCHEMBL5955117 0.83 ALDH1A1 (0.64) NPC1RAB9ALTA4HSMN1; SMN2MEN1
SCHEMBL11649939 0.81 ALDH1A1 (0.66) SMN1; SMN2MEN1KMT2AMAPTNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11197854-B1 Inhibitors for targeting flaviviruses NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2021-12-14 — — US disclosed
US-8338469-B2 Compounds and compositions as channel activating protease inhibitors IRM LLC (BM) 2012-12-25 — — US disclosed
US-20110257077-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2011-10-20 — — US disclosed
US-7951823-B2 Compounds and compositions as channel activating protease inhibitors IRM LLC (BM) 2011-05-31 — — US disclosed
EP-2027143-A2 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2009-02-25 — — EP disclosed
WO-2007137080-A2 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS IRM LLC (BM) 2007-11-29 — — WO disclosed
US-20070275906-A1 Compounds and Compositions as Channel Activating Protease Inhibitors IRM LLC (BM) 2007-11-29 — — US disclosed
EP-1362855-B1 BETA-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2007-10-03 — — EP disclosed
US-7109243-B2 Inhibitors of cathepsin S IRM LLC (BM) 2006-09-19 — — US disclosed
US-7045515-B2 β-lactam compounds process for reproducing the same and serum cholesterol-lowering agents containing the same KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2006-05-16 — — US disclosed
US-5606071-A Process for preparing 5-arylhydantoins using 5-hydantoin, a halogenating agent and p-phenol SHOWA DENKO K.K. (JP) 1997-02-25 — — US disclosed
EP-0748320-A1 PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1996-12-18 — — EP disclosed
EP-0734381-A1 MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO. INC. (US) 1996-10-02 — — EP disclosed
US-5512570-A Treatment of emesis with morpholine tachykinin receptor antagonists MERCK & CO., INC. (US) 1996-04-30 — — US disclosed
WO-1995023798-A1 PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-09-08 — — WO disclosed
WO-1995016679-A1 MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-06-22 — — WO disclosed
EP-0647630-A1 Process for producing 5-arylhydantoins SHOWA DENKO KABUSHIKI KAISHA (JP) 1995-04-12 — — EP disclosed
US-4692512-A FOODS AND BEVERAGES THE PROCTER & GAMBLE COMPANY (US) 1987-09-08 — — US disclosed
EP-0168112-A2 Alpha-L-aspartyl-D-phenylglycine esters and amides useful as high intensity sweeteners THE PROCTER & GAMBLE COMPANY (US) 1986-01-15 — — EP disclosed
US-4075219-A Epimerization process ELI LILLY AND COMPANY (US) 1978-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11197854-B1 Inhibitors for targeting flaviviruses HAVCR2, MME, SPINT2 NPC1 173/4885RAB9A 960/4885LTA4H 2470/4885
US-20110257077-A1 COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS PRSS1, PRSS8, PRSS2 NPC1 726/4885RAB9A 3044/4885LTA4H 207/4885
US-20070275906-A1 Compounds and Compositions as Channel Activating Protease Inhibitors PRSS1, PRSS8, PRSS2 NPC1 726/4885RAB9A 3044/4885LTA4H 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.